Malignant Neoplasms
FDA Halts BioNTech-MediLink ADC Trial Due to ‘Significant Risk of Illness or Injuries’
FDA, BioNTech, MediLink, ADC, Clinical Trial, Safety Concerns, Cancer Treatment
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns
ASCO: AbbVie Revamps ADC Portfolio to Replace Chemotherapy
ASCO, AbbVie, ADCs, Chemotherapy, Rova-T, Teliso-V, Cancer Treatment
Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO
Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment
Illumina’s Board Approves Spin-Off of Grail, a Cancer Diagnostics Firm
Illumina, Grail, spin-off, cancer diagnostics, DNA sequencing
GSK Faces Major Setback in Zantac Litigation as Judge Allows Over 70,000 Lawsuits to Proceed
GSK, Zantac, Lawsuits, Cancer, Delaware Court, Judge Vivian Medinilla, Ranitidine, NDMA, Pharmaceuticals
ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies
ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.
ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment
ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment
FDA Grants De Novo Clearance to Scopio Labs’ AI-Powered Bone Marrow Pathology Application for Blood Disorders and Cancer
Scopio Labs, De Novo Clearance, FDA, Bone Marrow Pathology, AI, Blood Disorders, Cancer